Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 11/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729936 | 0.86 | CYP19A1 (0.45) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL732525 | 0.83 | CYP11B2 (0.43) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL1040981 | 0.83 | CYP11B2 (0.62) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL13524655 | 0.81 | CYP11B2 (0.64) | CYP11B2CYP19A1CYP11B1KCNH2 | |
| SCHEMBL730388 | 0.78 | CYP19A1 (0.65) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL27861938 | 0.76 | CYP11B2 (0.62) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL731942 | 0.73 | CYP19A1 (0.38) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL730400 | 0.72 | CYP11B2 (0.43) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL16205314 | 0.72 | CYP19A1 (0.57) | CYP11B2CYP19A1CYP11B1KCNH2CYP17A1 | |
| SCHEMBL732474 | 0.71 | CYP19A1 (0.46) | CYP11B2CYP19A1CYP11B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | CYP11B2 2/4885CYP19A1 70/4885CYP11B1 3/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | CYP11B2 2/4885CYP19A1 84/4885CYP11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.